Akums Drugs & Pharmaceuticals Ltd
AKUMS NSE
Akums Drugs & Pharmaceuticals Ltd
HealthcareNSE: AKUMS BSE: 544222 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹11,796 Cr
Volatility
Moderate
P/E Ratio
40.16
EBITDA
₹651 Cr
Return on Equity
7.7%
Debt to Equity
0.05
Book Value
₹210.57
EPS
₹0
52W High
₹775
52W Low
₹409.3
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Akums Drugs & Pharmaceuticals Ltd insights
54 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
3- Stock is trading at 3.53 times its book value
- The company has delivered a poor sales growth of 9.87% over past five years.
- Company has a low return on equity of 9.89% over last 3 years.
Growth Rate
Revenue Growth
7.61% ↗
Net Income Growth
-25.42% ↘
Cash Flow Change
153.91% ↗
ROE
-31.37% ↘
ROCE
-7.29% ↘
EBITDA Margin (Avg.)
17.03% ↗
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 42d agoAI opinion · based on fundamentals
Risk medium
Akums Drugs & Pharmaceuticals trades at a market cap of ₹9,883 Cr with a PE of 38.4x and is nearly debt-free. However, recent TTM profit growth has turned negative at -14% and ROE remains modest at 8-10%, presenting a mixed picture for a healthcare CDMO player at this valuation.
Bull Case 7
- Company is almost debt-free, providing significant financial flexibility and low interest burden in a capital-intensive pharma sector
- Compounded profit growth of 29% over 3 years demonstrates strong earnings trajectory over the medium term
- Long-term compounded sales growth of 10% over both 5-year and 10-year periods shows consistent revenue expansion
- Compounded profit growth of 16% over both 5-year and 10-year horizons indicates sustainable long-term earnings compounding
- Dividend yield of 0.48% provides some income return, uncommon among growth-stage pharma companies
- Stock has delivered 8% CAGR over 1 year, indicating positive price momentum despite broader market volatility
- CDMO business model in India's growing pharmaceutical outsourcing market benefits from structural industry tailwinds with 10% long-term sales CAGR as evidence
Bear Case 8
- PE ratio of 38.4x is elevated for a company delivering only 6% TTM sales growth, suggesting stretched valuations
- TTM compounded profit growth has turned negative at -14%, indicating recent earnings deterioration
- Return on equity of just 9.72% over last 3 years is low for a company trading at 2.98x book value
- Recent sales growth has decelerated to 6% TTM from the 10% five-year CAGR, signaling a slowdown
- Price-to-book ratio of 2.97x is high relative to the modest 8% ROE delivered in the last year
- 5-year sales CAGR of 9.87% is considered poor growth for a mid-cap pharma company at premium valuations
- ROE has declined from 10% (3-year average) to 8% in the last year, showing deteriorating capital efficiency
- 5-year ROE average of only 6% suggests the company historically struggles to generate adequate returns on shareholder equity
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 42d ago Positives 1
- ₹3 dividend record date set Jun 16
Akums fixed July 3, 2026 as record date for a final and special dividend of ₹3 per share, subject to shareholder approval at the AGM on July 10.
Neutral 2
- BRSR FY26 ESG report filed Jun 18
Akums filed its Business Responsibility and Sustainability Report for FY 2025-26 detailing energy consumption, waste management, and employee welfare metrics.
- Investor meets in June Jun 10
Akums scheduled investor meetings in Singapore and Mumbai on June 15, and hosted the InsightX 2026 Virtual Conference on June 12 at 12:00 noon IST. No unpublished price sensitive information shared.
TL;DR: Akums is maintaining steady shareholder engagement through investor conferences and a ₹3 per share dividend announcement. No material headwinds surfaced in the recent news cycle. The company's proactive ESG reporting and capital return signal stable governance. Near-term catalysts depend on AGM approval of the dividend on July 10 and any strategic updates from investor interactions.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 970 | 1,181 | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 |
| Expenses | 1,095 | 1,029 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 992 |
| Operating Profit | -125 | 152 | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 175 |
| OPM % | -13% | 13% | 9% | 0.3% | 13% | 12% | 12% | 9% | 13% | 9% | 13% | 13% | 15% |
| Other Income | 8 | -21 | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 |
| Interest | 12 | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 |
| Depreciation | 30 | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 |
| PBT | -159 | 87 | 59 | -33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 |
| Tax % | 18% | 62% | -229% | 20% | 30% | 27% | 27% | -99% | 32% | 35% | 32% | 33% | 27% |
| Net Profit | -187 | 33 | 195 | -39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| EPS in Rs | -13.16 | 2.22 | 13.54 | -2.89 | 4.08 | 4.14 | 4.14 | 9.38 | 4.03 | 2.59 | 4.21 | 5.38 | 6.35 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,464 | 1,651 | 2,414 | 2,723 | 3,672 | 3,655 | 4,178 | 4,118 | 4,359 | 4,502 |
| Expenses | 1,340 | 1,507 | 2,240 | 2,485 | 3,761 | 3,361 | 4,055 | 3,654 | 3,837 | 3,934 |
| Operating Profit | 124 | 144 | 174 | 238 | -89 | 294 | 123 | 465 | 522 | 568 |
| OPM % | 8% | 9% | 7% | 9% | -2.4% | 8% | 3% | 11% | 12% | 13% |
| Other Income | 6 | 6 | 26 | 11 | 7 | 15 | 8 | 69 | 108 | 112 |
| Interest | 23 | 22 | 20 | 7 | 17 | 46 | 51 | 35 | 94 | 96 |
| Depreciation | 31 | 38 | 67 | 70 | 95 | 113 | 126 | 153 | 155 | 159 |
| PBT | 77 | 89 | 114 | 172 | -193 | 150 | -45 | 345 | 382 | 426 |
| Tax % | 51% | 50% | 62% | 28% | 30% | 35% | -102% | 0% | 33% | — |
| Net Profit | 43 | 61 | 44 | 123 | -251 | 98 | 1 | 344 | 256 | 293 |
| EPS in Rs | 367 | 523 | 336 | 943 | -35.3 | 6.63 | -0.28 | 21.49 | 16.21 | 18.53 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 18% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 14 | 29 | 29 | 31 | 31 |
| Reserves | 493 | 628 | 721 | 884 | 608 | 689 | 681 | 3,016 | 3,283 |
| Borrowings | 255 | 213 | 175 | 130 | 395 | 619 | 565 | 88 | 157 |
| Other Liabilities | 293 | 318 | 1,140 | 1,137 | 2,033 | 1,905 | 2,229 | 960 | 1,958 |
| Total Liabilities | 1,042 | 1,161 | 2,037 | 2,152 | 3,050 | 3,241 | 3,504 | 4,095 | 5,429 |
| Fixed Assets | 444 | 501 | 645 | 904 | 1,021 | 1,097 | 1,191 | 1,397 | 1,456 |
| CWIP | 0 | 11 | 57 | 17 | 31 | 103 | 195 | 163 | 177 |
| Investments | 0 | 18 | 6 | 20 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 598 | 632 | 1,329 | 1,212 | 1,998 | 2,041 | 2,118 | 2,535 | 3,796 |
| Total Assets | 1,042 | 1,161 | 2,037 | 2,152 | 3,050 | 3,241 | 3,504 | 4,095 | 5,429 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 72 | 89 | 28 | 131 | 32 | 177 | 498 | 465 | 1,181 |
| Investing | -150 | -123 | -190 | -109 | -235 | -305 | -331 | -548 | -930 |
| Financing | 66 | 37 | 233 | -91 | 236 | 125 | -108 | 73 | 34 |
| Net Cash Flow | -11 | 4 | 71 | -70 | 33 | -4 | 59 | -10 | 285 |
| Free Cash Flow | -78 | -34 | -34 | 49 | -224 | -110 | 212 | 201 | 958 |
| CFO/OP | 72 | 98 | 44 | 74 | -98 | 93 | 455 | 118 | 243 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 57 | 88 | 71 | 88 | 84 | 73 | 68 | 67 |
| Inventory Days | 114 | 115 | 99 | 93 | 112 | 117 | 90 | 102 | 110 |
| Days Payable | 67 | 60 | 105 | 74 | 92 | 91 | 76 | 96 | 87 |
| Cash Conversion Cycle | 115 | 112 | 82 | 90 | 109 | 111 | 87 | 74 | 89 |
| Working Capital Days | 78 | 73 | 55 | 66 | 49 | 46 | 40 | 71 | 66 |
| ROCE % | — | 14% | — | 20% | -16% | 22% | 2% | 16% | 15% |
Documents
1
Board Meeting Intimation for Board Meeting Intimation
4h - Board meets May 14, 2026 to approve FY26 audited results and consider dividend. 4h - Board meets May 14, 2026 to approve FY26 audited results and consider dividend.
2
ESG Rating
8 May - Akums received unsolicited ESG rating of 63 for FY2024-25 from NSE Sustainability on 7 May 2026. 8 May - Akums received unsolicited ESG rating of 63 for FY2024-25 from NSE Sustainability on 7 May 2026.
3
Execution Of Lease Deed
29 Apr - Pure and Cure Healthcare leased 4,050 sq. m industrial plot at Haridwar on April 28, 2026. 29 Apr - Pure and Cure Healthcare leased 4,050 sq. m industrial plot at Haridwar on April 28, 2026.
4
Execution Of Lease Deed
29 Apr - Pure and Cure Healthcare leased 4,050 sq. m industrial plot at Haridwar on April 28, 2026. 29 Apr - Pure and Cure Healthcare leased 4,050 sq. m industrial plot at Haridwar on April 28, 2026.
5
Announcement under Regulation 30 (LODR)-Credit Rating
11 Apr - ICRA reaffirmed AA (Stable)/A1+ for working capital limits and assigned A1+ to ₹200 crore CP programme. 11 Apr - ICRA reaffirmed AA (Stable)/A1+ for working capital limits and assigned A1+ to ₹200 crore CP programme.
Frequently Asked Questions about Akums Drugs & Pharmaceuticals Ltd
What does Akums Drugs & Pharmaceuticals Ltd do?
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]
Where is Akums Drugs & Pharmaceuticals Ltd (AKUMS) listed?
Akums Drugs & Pharmaceuticals Ltd is listed on the Indian stock exchanges. It is listed on NSE: AKUMS and BSE: 544222. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Akums Drugs & Pharmaceuticals Ltd belong to?
Akums Drugs & Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has a market capitalisation of approximately ₹11795.89 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Akums Drugs & Pharmaceuticals Ltd?
The Price-to-Earnings (PE) ratio of Akums Drugs & Pharmaceuticals Ltd is 40.16. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Akums Drugs & Pharmaceuticals Ltd?
Over the past 52 weeks, Akums Drugs & Pharmaceuticals Ltd has traded between a low of ₹409.3 and a high of ₹775. This range helps investors understand the stock's price volatility and recent trading levels.
Does Akums Drugs & Pharmaceuticals Ltd pay dividends?
Yes, Akums Drugs & Pharmaceuticals Ltd has a dividend yield of 0.40%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has a Return on Equity (ROE) of 7.70%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Akums Drugs & Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view Akums Drugs & Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]
Website akums.in
CEO Mr. Sanjeev Jain
Employees 7,536
Listed 2024-08-06
Face Value ₹ 2
Issued Size 15,73,93,988